Timothy Yap

Timothy Yap

Company: MD Anderson Cancer Center

Job title: Associate Professor, Investigational Cancer Therapeutics


Closing Panel Discussion: Future Directions for DDRi 5:30 pm

What is the current status of DDRi combination with IO Thoughts and rationalizing on potential best outcomes DDR-DDR combos Reviewing the various combination approaches and new targets coming in – thought experiment based on pathway What are the combinations and new targets that are going to push the field forward in a durable and effective…Read more

day: Day Two

Targeting ATR in the Clinic: Novel Agents and Rational Combinations 5:00 pm

• ATR inhibitors are a promising antitumor therapy • Patient selection is critical to optimize antitumor efficacy • Rational combinations will enhance the efficacy and reach of ATR inhibitorsRead more

day: Day Two

Panel Discussion: A Comparison; The Challenges & Learnings of Developing ATR inhibitors – What Clinical Space Will They Occupy? 2:20 pm

Analyzing the current applications of these inhibitors both in preclinical and clinical studies either as single agents or in combinations with chemotherapy, radiotherapy and immunotherapy Dissecting toxicity profiles (bone marrow toxicity?) Opening the ATR inhibitor black box: what clinical space will they occupy? Understanding biomarker indications for ATR sensitivity: Cyclin E, ATM Loss? not as…Read more

day: Day One

ATRi’s: Latest Clinical Trial Data 11:00 am

Read more

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.